!
!
Sign in / Join ICS
Home
A next generation drug for Overactive bladder, TRK-130, in a Phase-IIb clinical trial in Japan; Preclinical data of potent pharmacological effects based on modulation of neurotransmission.
Kawai K
1
, Fujimura M
1
, Kanie S
1
, Momen S
1
, Izumimoto N
1
, Iwata M
2
, Okanishi S
2
, Hashimoto T
2
, Awasaki Y
2
, Nishida N
2
, Sasaki M
3
, Yanagita T
4
Abstract Category
Neurourology: Basic Science
Abstract 177
Urothelium and Signal Transmission
Scientific Podium Poster Session 17
Thursday 1st September 2011
16:30 - 16:35
Hall P4
1.
Toray Industries Inc. Pharmaceutical Research Laboratories,
2.
Takeda Pharmaceutical Company Limited,
3.
Ina research Inc.,
4.
Jikei University School of Medicine
Presenter
K
Koji Kawai
Links
Abstract PDF
Edit Abstract
Abstract Centre
Abstract
24/08/2024 10:04:20